174 related articles for article (PubMed ID: 38156586)
1. [Epstein-Barr virus (Herpesviridae:
Smirnova KV; Lubenskaya AK; Senyuta NB; Dushenkina TE; Gurtsevitch VE
Vopr Virusol; 2023 Sep; 68(4):291-301. PubMed ID: 38156586
[TBL] [Abstract][Full Text] [Related]
2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
[TBL] [Abstract][Full Text] [Related]
4. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
7. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
[TBL] [Abstract][Full Text] [Related]
8. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
9. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
[TBL] [Abstract][Full Text] [Related]
10. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
[TBL] [Abstract][Full Text] [Related]
11. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
[TBL] [Abstract][Full Text] [Related]
12. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.
Gurtsevitch VE; Senyuta NB; Ignatova AV; Lomaya MV; Kondratova VN; Pavlovskaya AI; Dushenkina TE; Maximovich DM; Smirnova KV; Mudunov AM; Lichtenstein AV
J Gen Virol; 2017 Aug; 98(8):2118-2127. PubMed ID: 28786806
[TBL] [Abstract][Full Text] [Related]
15. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.
Fachiroh J; Schouten T; Hariwiyanto B; Paramita DK; Harijadi A; Haryana SM; Ng MH; Middeldorp JM
J Infect Dis; 2004 Jul; 190(1):53-62. PubMed ID: 15195243
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
[TBL] [Abstract][Full Text] [Related]
17. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.
Simon J; Brenner N; Reich S; Langseth H; Hansen BT; Ursin G; Ferreiro-Iglesias A; Brennan P; Kreimer AR; Johansson M; Pring M; Nygard M; Waterboer T
Cancer Epidemiol; 2022 Apr; 77():102117. PubMed ID: 35121404
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
[TBL] [Abstract][Full Text] [Related]
19. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
[TBL] [Abstract][Full Text] [Related]
20. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.
Diao H; Xue WQ; Wang TM; Yang DW; Deng CM; Li DH; Zhang WL; Liao Y; Wu YX; Chen XY; Zhou T; Li XZ; Zhang PF; Zheng XH; Zhang SD; Hu YZ; Cao SM; Liu Q; Ye WM; He YQ; Jia WH
J Med Virol; 2023 Nov; 95(11):e29224. PubMed ID: 37970759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
